Navigation Links
Echo Therapeutics Announces New Presentation Time at Rodman & Renshaw 2009 Annual Global Investment Conference
Date:9/9/2009

FRANKLIN, Mass., Sept. 9 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a diabetes management company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that it has rescheduled the Company's presentation at the Rodman & Renshaw 2009 Annual Global Investment Conference. Patrick T. Mooney, M.D., Chairman and Chief Executive Officer, will now present on Thursday, September 10, 2009 at 11:15am ET. The presentation will occur live and will be held at The New York Palace Hotel in New York, NY.

About Echo Therapeutics

Echo Therapeutics is focused on medical devices and specialty pharmaceuticals. Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the efficacy of Echo's Symphony tCGM System and Prelude SkinPrep System, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM System and Prelude SkinPrep System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM System and Prelude SkinPrep System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM System and its Prelude SkinPrep System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2008, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo Therapeutics, Inc. undertakes no obligation to publicly update or revise any forward-looking statements.

www.echotx.com

    For More Information:
    Patrick T. Mooney, M.D.
    Chairman and Chief Executive Officer
    (508)-530-0329


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Chief Executive Officer and Vice President Commercial Operations USA at the Helsinn Groups American subsidiary, Helsinn Therapeutics (U.S.) Inc.
2. Cell Therapeutics, Inc.s (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast
3. Reportlinker Adds Autoimmune Disease Therapeutics Report
4. Reportlinker Adds Lung Cancer Therapeutics Report
5. Reportlinker Adds Therapeutics for Memory and Cognition Disorders Report
6. Reportlinker Adds Therapeutics and Diagnostics for Womens Disorders Report
7. Reportlinker Adds Dermatological Therapeutics: Global Markets Report
8. Echo Therapeutics to Present at Rodman & Renshaw 2009 Annual Global Investment Conference
9. Cornerstone Therapeutics to Present at Two Upcoming Investor Conferences
10. Selexis and NKT Therapeutics Enter Into Research Services Agreement
11. FDA Accepts to File Cell Therapeutics New Drug Application for Pixantrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , ... December 05, 2016 ... ... Great Point Partners ("GPP") portfolio company, today announced it has acquired the ... TCS was previously a subsidiary of Chiltern International and focuses on ...
(Date:12/5/2016)... ... December 05, 2016 , ... Sabah Shah MD, MBA has joined the Retina Group ... New York was founded by James M. Maisel, MD and has been providing tertiary medical ... always followed a legacy of surpassing expectations amongst her peers. Growing up in a ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... "Best Surgical Facial Rejuvenation" at the 2016 Anti-Aging & Beauty Awards at ... , The Aesthetic & Anti-aging Medicine European Congress (AMEC) brings together the ...
(Date:12/4/2016)... New York, NY (PRWEB) , ... December 03, ... ... nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving ... patient services – hosted its first Swirl: A Wine Tasting Event in New ...
(Date:12/4/2016)... ... 03, 2016 , ... Penrose Senior Care Auditors® was announced ... evening at the 26th Annual SMU Cox Dallas 100™ Awards Ceremony and Banquet ... for Entrepreneurship. Dallas 100™, co-founded by the Caruth Institute, honors the ingenuity, commitment ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... and Gateway Health proudly announce a dynamic collaboration that will ... members with specific high risk needs. In an ... of consumers, Wellbridge combines technology and population expertise with a ... daily behaviors and lifestyle. ... , , "Dealing ...
(Date:12/5/2016)... Dec. 5, 2016  New research by the ... Institute and the U.S. Department of Health and ... Preparedness and Response (ASPR), published online today in ... pharmacy notifications encourage patients with chronic conditions to ... The study also affirms that public-private partnerships can ...
(Date:12/5/2016)... VEGAS , Dec. 5, 2016  BD (Becton, ... leading global medical technology company, will demonstrate an enhanced ... medication management technologies, including the company,s leading Pyxis™ and ... Health-System Pharmacists (ASHP) 2016 Midyear Meeting being held ... 4-8. While national data show that approximately ...
Breaking Medicine Technology: